世界の一次進行性多発性硬化症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Primary Progressive Multiple Sclerosis Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4790
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、94ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、一次進行性多発性硬化症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・一次進行性多発性硬化症治療の市場動向
・企業の競争状況、市場シェア
・一次進行性多発性硬化症治療の種類別市場規模（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）
・一次進行性多発性硬化症治療の用途別市場規模（病院、診療所、その他）
・一次進行性多発性硬化症治療の北米市場規模2016-2027（アメリカ、カナダ）
・一次進行性多発性硬化症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・一次進行性多発性硬化症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・一次進行性多発性硬化症治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・一次進行性多発性硬化症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Kyorin Pharmaceutical Co., Ltd.、MedDay SA、Santhera Pharmaceuticals Holding AG、Teva Pharmaceutical Industries Ltd.）
・結論

Market Analysis and Insights: Global Primary Progressive Multiple Sclerosis Treatment Market
The global Primary Progressive Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Progressive Multiple Sclerosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Progressive Multiple Sclerosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Progressive Multiple Sclerosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Progressive Multiple Sclerosis Treatment market.

Global Primary Progressive Multiple Sclerosis Treatment Scope and Market Size
Primary Progressive Multiple Sclerosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Progressive Multiple Sclerosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
ApE
Biotin
GZ-402668
Ibudilast
Idebenone
Laquinimod Sodium
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Kyorin Pharmaceutical Co., Ltd.
MedDay SA
Santhera Pharmaceuticals Holding AG
Teva Pharmaceutical Industries Ltd.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 ApE
1.2.3 Biotin
1.2.4 GZ-402668
1.2.5 Ibudilast
1.2.6 Idebenone
1.2.7 Laquinimod Sodium
1.2.8 Others
1.3 Market by Application
1.3.1 Global Primary Progressive Multiple Sclerosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Primary Progressive Multiple Sclerosis Treatment Market Perspective (2016-2027)
2.2 Primary Progressive Multiple Sclerosis Treatment Growth Trends by Regions
2.2.1 Primary Progressive Multiple Sclerosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Primary Progressive Multiple Sclerosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Primary Progressive Multiple Sclerosis Treatment Industry Dynamic
2.3.1 Primary Progressive Multiple Sclerosis Treatment Market Trends
2.3.2 Primary Progressive Multiple Sclerosis Treatment Market Drivers
2.3.3 Primary Progressive Multiple Sclerosis Treatment Market Challenges
2.3.4 Primary Progressive Multiple Sclerosis Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Primary Progressive Multiple Sclerosis Treatment Players by Revenue
3.1.1 Global Top Primary Progressive Multiple Sclerosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Primary Progressive Multiple Sclerosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Primary Progressive Multiple Sclerosis Treatment Revenue
3.4 Global Primary Progressive Multiple Sclerosis Treatment Market Concentration Ratio
3.4.1 Global Primary Progressive Multiple Sclerosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Progressive Multiple Sclerosis Treatment Revenue in 2020
3.5 Primary Progressive Multiple Sclerosis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Progressive Multiple Sclerosis Treatment Product Solution and Service
3.7 Date of Enter into Primary Progressive Multiple Sclerosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Primary Progressive Multiple Sclerosis Treatment Breakdown Data by Type
4.1 Global Primary Progressive Multiple Sclerosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Type (2022-2027)

5 Primary Progressive Multiple Sclerosis Treatment Breakdown Data by Application
5.1 Global Primary Progressive Multiple Sclerosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Primary Progressive Multiple Sclerosis Treatment Market Size (2016-2027)
6.2 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type
6.2.1 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2027)
6.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application
6.3.1 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2027)
6.4 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country
6.4.1 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Primary Progressive Multiple Sclerosis Treatment Market Size (2016-2027)
7.2 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type
7.2.1 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2027)
7.3 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application
7.3.1 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2027)
7.4 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country
7.4.1 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type
8.2.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application
8.3.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region
8.4.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size (2016-2027)
9.2 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type
9.2.1 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application
9.3.1 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Country
9.4.1 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type
10.2.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application
10.3.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country
10.4.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 F. Hoffmann-La Roche Ltd. Company Details
11.1.2 F. Hoffmann-La Roche Ltd. Business Overview
11.1.3 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
11.1.4 F. Hoffmann-La Roche Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Ltd. Recent Development
11.2 Genzyme Corporation
11.2.1 Genzyme Corporation Company Details
11.2.2 Genzyme Corporation Business Overview
11.2.3 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Introduction
11.2.4 Genzyme Corporation Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.2.5 Genzyme Corporation Recent Development
11.3 Glialogix, Inc.
11.3.1 Glialogix, Inc. Company Details
11.3.2 Glialogix, Inc. Business Overview
11.3.3 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Introduction
11.3.4 Glialogix, Inc. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.3.5 Glialogix, Inc. Recent Development
11.4 Kyorin Pharmaceutical Co., Ltd.
11.4.1 Kyorin Pharmaceutical Co., Ltd. Company Details
11.4.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
11.4.3 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
11.4.4 Kyorin Pharmaceutical Co., Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.4.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
11.5 MedDay SA
11.5.1 MedDay SA Company Details
11.5.2 MedDay SA Business Overview
11.5.3 MedDay SA Primary Progressive Multiple Sclerosis Treatment Introduction
11.5.4 MedDay SA Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.5.5 MedDay SA Recent Development
11.6 Santhera Pharmaceuticals Holding AG
11.6.1 Santhera Pharmaceuticals Holding AG Company Details
11.6.2 Santhera Pharmaceuticals Holding AG Business Overview
11.6.3 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Introduction
11.6.4 Santhera Pharmaceuticals Holding AG Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.6.5 Santhera Pharmaceuticals Holding AG Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Details
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of ApE
Table 3. Key Players of Biotin
Table 4. Key Players of GZ-402668
Table 5. Key Players of Ibudilast
Table 6. Key Players of Idebenone
Table 7. Key Players of Laquinimod Sodium
Table 8. Key Players of Others
Table 9. Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2016-2021)
Table 13. Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2022-2027)
Table 15. Primary Progressive Multiple Sclerosis Treatment Market Trends
Table 16. Primary Progressive Multiple Sclerosis Treatment Market Drivers
Table 17. Primary Progressive Multiple Sclerosis Treatment Market Challenges
Table 18. Primary Progressive Multiple Sclerosis Treatment Market Restraints
Table 19. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Players (2016-2021)
Table 21. Global Top Primary Progressive Multiple Sclerosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Progressive Multiple Sclerosis Treatment as of 2020)
Table 22. Ranking of Global Top Primary Progressive Multiple Sclerosis Treatment Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Primary Progressive Multiple Sclerosis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Primary Progressive Multiple Sclerosis Treatment Product Solution and Service
Table 26. Date of Enter into Primary Progressive Multiple Sclerosis Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type (2016-2021)
Table 30. Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Primary Progressive Multiple Sclerosis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application (2016-2021)
Table 34. Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 66. F. Hoffmann-La Roche Ltd. Company Details
Table 67. F. Hoffmann-La Roche Ltd. Business Overview
Table 68. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Product
Table 69. F. Hoffmann-La Roche Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 70. F. Hoffmann-La Roche Ltd. Recent Development
Table 71. Genzyme Corporation Company Details
Table 72. Genzyme Corporation Business Overview
Table 73. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product
Table 74. Genzyme Corporation Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 75. Genzyme Corporation Recent Development
Table 76. Glialogix, Inc. Company Details
Table 77. Glialogix, Inc. Business Overview
Table 78. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Product
Table 79. Glialogix, Inc. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 80. Glialogix, Inc. Recent Development
Table 81. Kyorin Pharmaceutical Co., Ltd. Company Details
Table 82. Kyorin Pharmaceutical Co., Ltd. Business Overview
Table 83. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Product
Table 84. Kyorin Pharmaceutical Co., Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 85. Kyorin Pharmaceutical Co., Ltd. Recent Development
Table 86. MedDay SA Company Details
Table 87. MedDay SA Business Overview
Table 88. MedDay SA Primary Progressive Multiple Sclerosis Treatment Product
Table 89. MedDay SA Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 90. MedDay SA Recent Development
Table 91. Santhera Pharmaceuticals Holding AG Company Details
Table 92. Santhera Pharmaceuticals Holding AG Business Overview
Table 93. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product
Table 94. Santhera Pharmaceuticals Holding AG Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 95. Santhera Pharmaceuticals Holding AG Recent Development
Table 96. Teva Pharmaceutical Industries Ltd. Company Details
Table 97. Teva Pharmaceutical Industries Ltd. Business Overview
Table 98. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Product
Table 99. Teva Pharmaceutical Industries Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021) & (US$ Million)
Table 100. Teva Pharmaceutical Industries Ltd. Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Type: 2020 VS 2027
Figure 2. ApE Features
Figure 3. Biotin Features
Figure 4. GZ-402668 Features
Figure 5. Ibudilast Features
Figure 6. Idebenone Features
Figure 7. Laquinimod Sodium Features
Figure 8. Others Features
Figure 9. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Application: 2020 VS 2027
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Others Case Studies
Figure 13. Primary Progressive Multiple Sclerosis Treatment Report Years Considered
Figure 14. Global Primary Progressive Multiple Sclerosis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Primary Progressive Multiple Sclerosis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions: 2020 VS 2027
Figure 17. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2022-2027)
Figure 18. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Players in 2020
Figure 19. Global Top Primary Progressive Multiple Sclerosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Progressive Multiple Sclerosis Treatment as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Primary Progressive Multiple Sclerosis Treatment Revenue in 2020
Figure 21. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type (2016-2021)
Figure 22. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type (2022-2027)
Figure 23. North America Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2016-2027)
Figure 25. North America Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2016-2027)
Figure 26. North America Primary Progressive Multiple Sclerosis Treatment Market Share by Country (2016-2027)
Figure 27. United States Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2016-2027)
Figure 31. Europe Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2016-2027)
Figure 32. Europe Primary Progressive Multiple Sclerosis Treatment Market Share by Country (2016-2027)
Figure 33. Germany Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Market Share by Region (2016-2027)
Figure 43. China Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2016-2027)
Figure 51. Latin America Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2016-2027)
Figure 52. Latin America Primary Progressive Multiple Sclerosis Treatment Market Share by Country (2016-2027)
Figure 53. Mexico Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Share by Country (2016-2027)
Figure 59. Turkey Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 63. Genzyme Corporation Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 64. Glialogix, Inc. Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 65. Kyorin Pharmaceutical Co., Ltd. Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 66. MedDay SA Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 67. Santhera Pharmaceuticals Holding AG Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 68. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Primary Progressive Multiple Sclerosis Treatment Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Global Progressive Relapsing Multiple Sclerosis Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4818 2021年4月 99Pages
QYResearch社発行の本調査資料では、進行性再発性多発性硬化症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（COG-133、GZ-402668、イネビリズマブ、VCE-0032、その他）、用途別市場規模（診療所、病院、その他）、主要...

世界の多発性硬化症治療市場規模・現状・予測（2021年-2027年）

Global Multiple Sclerosis Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3956 2021年4月 93Pages
QYResearch社発行の本調査資料では、多発性硬化症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫調節剤、免疫抑制剤）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国...

世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年）

Global Stem Cell Therapy for Multiple Sclerosis Market Size, Status and Forecast 2021-2027
QYR2104Z5441 2021年4月 90Pages
QYResearch社発行の本調査資料では、多発性硬化症幹細胞治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（静脈内、脳室内）、用途別市場規模（再発寛解型多発性硬化症（RRMS）、一次進行型多発性硬化症（PPMS）、二次性進行型多発性硬化症...

世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年）

世界の多発性硬化症治療市場規模・現状・予測（2021年-2027年）

Global Multiple Sclerosis Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z3955 2021年4月 90Pages
QYResearch社発行の本調査資料では、多発性硬化症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ベータインターフェロン、コルチコステロイド、モノクローナル抗体、抗腫瘍剤、その他）、用途別市場規模（病院薬局、小売薬局、eコマース）、主...

世界の多発性硬化症治療市場規模・現状・予測（2021年-2027年）

世界の進行性運動失調及び脱力障害症候群治療市場規模・現状・予測（2021年-2027年）

Global Treatment for Syndromes of Progressive Ataxia and Weakness Disorders Market Size, Status and Forecast 2021-2027
QYR2104Z5740 2021年4月 98Pages
QYResearch社発行の本調査資料では、進行性運動失調及び脱力障害症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、小分子技術）、用途別市場規模（フリードライヒ運動失調症、遺伝性ニューロパチー、マチャドジョセフ病...

世界の進行性多巣性白質脳症治療市場規模・現状・予測（2021年-2027年）

Global Progressive Multifocal Leukoencephalopathy Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4817 2021年4月 94Pages
QYResearch社発行の本調査資料では、進行性多巣性白質脳症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗レトロウイルス療法、抗ウイルス/抗JCV、その他）、用途別市場規模（病院薬局、ドラッグストア、小売薬局）、主要地域別市場規模（...

世界の筋萎縮性側索硬化症（ルーゲーリック病）治療市場規模・現状・予測（2021年-2027年）

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z0301 2021年4月 90Pages
QYResearch社発行の本調査資料では、筋萎縮性側索硬化症（ルーゲーリック病）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、幹細胞治療）、用途別市場規模（病院、診断センター、クリニック、小売薬局）、主要地域別市場規模（北米、...

世界の筋萎縮性側索硬化症（ルーゲーリック病）治療市場規模・現状・予測（2021年-2027年）

世界の進行性再発性多発性硬化症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Progressive Relapsing Multiple Sclerosis Treatment Market The global Progressive Relapsing Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standar…
世界の多発性硬化症治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and somet…
世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
世界の多発性硬化症幹細胞治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
世界の多発性硬化症治療市場規模・現状・予測（2021年-2027年） Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the d…